Table 1 Characteristics of included studies
Trail | Sample size (T/C) | Age (y), mean ± SD or median (range) | Diagnostic criteria | T | C | Duration | Main outcomes | |
|---|---|---|---|---|---|---|---|---|
T | C | |||||||
Li et al. [13] | 30/30 | 61.0 ± 8.14 | 60.97 ± 7.49 | COA | diacerein | diclofenacSodium | 12 weeks | ①②③ |
Chen et al. [14] | 70/70 | 55.99 ± 10.47 | 56.77 ± 10.60 | COA | diacerein | celecoxib | 12 weeks | ①② |
Wang [15] | 37/38 | 58.2 ± 10.7 | ACR | diacerein | diclofenacSodium | 12 weeks | ③ | |
Chen et al. [16] | 32/30 | 63(45–75) | ACR | diacerein | Loxoprofen | 12 weeks | ③ | |
Chen [17] | 18/18 | 56.57 ± 5.51 | COA | Diacerein | celecoxib | 12 weeks | ①③ | |
Ma [18] | 37/38 | 55.3 ± 6.9 | 54.6 ± 7.1 | ACR | diacerein | meloxicam | 12 weeks | ①②③ |
Zhang et al. [19] | 21/21 | 43–73 | 46–72 | ACR | diacerein | diclofenacSodium | 12 weeks | ①②③④ |
Ye and Xue [20] | 180/180 | 40–65 | ACR | diacerein | piroxicam | 16 weeks | ①②③④ | |
Tian et al. [21] | 54/54 | NR | ACR | diacerein | diclofenacSodium | 12 weeks | â‘ â‘¡â‘¢ | |
Pelletier et al. [22] | 187/193 | 63.7 ± 6.3 | 64.4 ± 7.0 | ACR | diacerein | Celecoxib | 24 weeks | ①②③ |
Zheng et al. [23] | 111/112 | 58.22 ± 8.42 | 59.49 ± 8.56 | ACR | diacerein | diclofenacSodium | 12 weeks | ①②③④ |
Louthrenoo et al. [24] | 86/85 | 54 ± 6.2 | 54 ± 7.0 | ACR | diacerein | Piroxicam | 16 weeks | ①③④ |